Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Exaggerated blood pressure responses to exercise in individuals with Type 2 Diabetes significantly increase the risk of heart attack, stroke, and cardiovascular death, while also limiting exercise capacity and therapeutic benefits of physical activity. This research will determine whether impaired blood vessel function and excessive cellular damage from oxygen-containing molecules cause these dangerous blood pressure responses during exercise. The findings will establish whether targeting cellular antioxidant systems represents a new therapeutic approach to improve exercise tolerance and reduce cardiovascular risk in t Americans living with diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Antioxidant Supplementation | Experimental | MitoQ, a mitochondrial target antioxidant, given once at a dose of 160 mg |
|
| Placebo | Placebo Comparator | A placebo similar visually will be used to compare to MitoQ |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MitoQ (mitoquinol mesylate) | Dietary Supplement | During each testing session, the investigators will be measuring how one treatment of an over-the-counter antioxidant supplement affects blood flow and muscle function. One day participants will orally ingest an over-the-counter antioxidant supplement called MitoQ. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Arterial Pressure | Change in mean arterial pressure is measured in response to handgrip exercise and post-exercise circulatory occlusion | Prior to and 45 minutes following supplement |
| Heart Rate | Change in heart rate is measured in response to handgrip exercise and post-exercise circulatory occlusion | Prior to and 45 minutes following supplement |
| Measure | Description | Time Frame |
|---|---|---|
| Brachial Artery FMD | Brachial artery FMD a measure of endothelial function will be measured on the non-dominant arm | Prior to and 45 minutes following supplementation |
| Plasma MitoQ Concentration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| William E Hughes, Ph.D. | Medical College of Wisconsin | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C429014 | mitoquinone |
Not provided
Not provided
Not provided
Participants will be randomized to either active or placebo supplement, acting as their own control
Not provided
Not provided
Not provided
|
| Placebo | Dietary Supplement | During each testing session, the investigators will be measuring how one treatment of an over-the-counter antioxidant supplement affects blood flow and muscle function. One day participants will orally ingest an over-the-counter antioxidant supplement called MitoQ, while the other they will ingest a placebo |
|
Circulating concentrations of MitoQ is assessed in blood via venipuncture
| Prior to and 45 minutes following supplementation |
| Muscle Tissue Oxygenation | We will also place a near-infrared spectroscopy (NIRS) pad on the thenar eminence of the non-paretic hand to non-invasively measure tissue oxygenation via infrared light following the pneumatic forearm cuff inflation/deflation. | Prior to and 45 minutes following supplementation |
| D004700 | Endocrine System Diseases |